Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT Studies)

Transplantation

Volumn 91, Issue 9, 2011, Pages 976-983

  Vanrenterghem, Yves ^a   Bresnahan, Barbara ^b   Campistol, Josep ^c   Durrbach, Antoine ^d   Grinyó, Josep ^e   Neumayer, Hans Hellmut ^f   Lang, Philippe ^g   Larsen, Christian P ^h   Mancilla Urrea, Eduardo ⁱ   Pestana, José Medina ^j   Block, Alan ^k   Duan, Tao ^k   Glicklich, Alan ^k   Gujrathi, Sheila ^k   Vincenti, Flavio ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d BICÊTRE HOSPITAL   (France)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g HENRI MONDOR HOSPITAL   (France)

^h EMORY UNIVERSITY   (United States)

ⁱ INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^j HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^k BRISTOL MYERS SQUIBB   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Belatacept; Cardiovascular; Cholesterol; Cyclosporine A; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 79955544132     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820c10eb     Document Type: Article

References (66)

1. Gill JS, Abichandani R, Kausz AT, et al. Mortality after kidney transplant failure: The impact of non-immunologic factors. Kidney Int 2002; 62: 1875., United States Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. http://www.usrds.org/. 2009. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
2. Rosas SE, Mensah K, Weinstein RB, et al. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005; 5: 1942.
3. Jogestrand T, Fehrman-Ekholm I, Angelin B, et al. Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation. J Intern Med 1996; 239: 177.
4. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14: 648.
5. Martinez-Castelao A, Sarrias X, Bestard O, et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc 2005; 37: 3788.
6. Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: Morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004; 18: 596.
7. Cosio FG, Pelletier RP, Sedmak DD, et al. Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 1999; 56: 1912.
8. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival. JAMA 2000; 283: 633.
9. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217.
10. Ducloux D, Motte G, Kribs M, et al. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 2002; 57: 409.
11. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
12. Basile JN. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract 2009; 63: 656.
13. Cole EH, Johnston O, Rose CL, et al. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814.
14. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905.
15. Aull-Watschinger S, Konstantin H, Demetriou D, et al. Pre-transplant predictors of cerebrovascular events after kidney transplantation. Nephrol Dial Transplant 2008; 23: 1429.
16. Vanrenterghem YF, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209.
17. van den Ham EC, Kooman JP, Christiaans MH, et al. Weight changes after renal transplantation: A comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 2003; 16: 300.
18. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: The effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829.
19. Roland M, Gatault P, Doute C, et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 21: 523.
20. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
21. Schiel R, Heinrich S, Steiner T, et al. Post-transplant diabetes mellitus: Risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005; 9: 164.
22. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.NEngl J Med 2004; 351: 1296.
23. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47.
24. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745.
25. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
26. Durrbach A, Medina-Pestana JO, Pearson TC, et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010; 10: 547.
27. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A Phase III study of belatacept-based immunosuppression regimens vs. cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010; 10: 535.
28. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79: 1160.
29. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986.
30. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
31. Charpentier B, Groth CG, Backman L, et al. Bicetre hospital experience with sirolimus-based therapy in human renal transplantation: The Sirolimus European Renal Transplant Study. Transplant Proc 2003; 35: 58S.
32. Gaber AO, Kahan BD, Van Buren C, et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized trial. Transplantation 2008; 86: 1187.
33. Legendre C, Campistol JM, Squifflet JP, et al. Cardiovascular risk factors of sirolimus compared with cyclosporine: Early experience from two randomized trials in renal transplantation. Transplant Proc 2003; 35: 151S.
34. Nankivell BJ, Chapman JR, Bonovas G, et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457
35. Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension: Incidence, pathogenesis and management. Drug Saf 1999; 20: 437.
36. Lietz K, Lewandowski Z, Lao M, et al. Pretransplant and early posttransplant predictors of chronic allograft nephropathy in cadaveric kidney allograft-a single-center analysis of 1112 cases. Transpl Int 2004; 17: 78.
37. Diaz JM, Gich I, Bonfill X, et al. Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival. Transplant Proc 2009; 41: 2151.
38. Fellstrom B, Holdaas H, Jardine AG, et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005; 79: 205.
39. Akioka K, Takahara S, Ichikawa S, et al. Factors predicting long-term graft survival after kidney transplantation: Multicenter study in Japan. World J Surg 2005; 29: 249.
40. Berber I, Aydin C, Yigit B, et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc 2005; 37: 997.
41. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603.
42. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145.
43. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
44. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352.
45. SilvaHTJr, Yang HC, Abouljoud M, et al. One-year results with extendedrelease tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
46. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model. Am J Transplant 2002; 2: 551.
47. Mathis AS, Dave N, Knipp GT, et al. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004; 61: 565.
48. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413.
49. Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375.
50. Hanak V, Munoz J, Teague J, et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the lowdensity lipoprotein phenotype B. Am J Cardiol 2004; 94: 219.
51. Hsia SH, Pan D, Berookim P, et al. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 2006; 98: 1047.
52. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003; 10: 186.
53. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486.
54. National Kidney Foundation. Introduction, assessment of dyslipidemias, treating dyslipidemias, and research recommendations. Am J Kidney Dis 2003; 41: S11.
55. Hernandez D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706.
56. Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. Am J Transplant 2008; 8: 1871.
57. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
58. Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795.
59. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
60. Gonzalez-Posada JM, Hernandez D, Bayes GB, et al. Impact of diabetes mellitus on kidney transplant recipients in Spain. Nephrol Dial Transplant 2004; 19(suppl 3): iii57.
61. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
62. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: The role of immunosuppression. Transplant Proc 2008; 40: 1885.
63. Deleuze S, Garrigue V, Delmas S, et al. New onset dyslipidemia after renal transplantation: Is there a difference between tacrolimus and cyclosporine? Transplant Proc 2006; 38: 2311.
64. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
65. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
66. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206